Serological Study of An Imported Case of Middle East Respiratory Syndrome and His Close Contacts in China, 2015

Wen Ling Wang1, Hui Juan Wang1, Yao Deng1

  • 1Key Laboratory of Medical Virology and Virus Disease, National Health and Family Planning Commission of the People's Republic of China; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

Insights

The first Middle East respiratory syndrome (MERS) case in China showed antibody development. Close contacts did not develop MERS-CoV antibodies, indicating no MERS transmission occurred.

Area of Science:

  • Virology
  • Immunology
  • Epidemiology

Background:

  • The Middle East respiratory syndrome-coronavirus (MERS-CoV) poses a significant public health threat.
  • Understanding MERS-CoV transmission dynamics is crucial for effective control strategies.

Observation:

  • The first imported MERS case in China was identified in May 2015.
  • Antibody kinetics (IgG, IgM, neutralizing) were analyzed in the MERS patient before discharge.
  • Paired serum samples from 53 close contacts were tested for MERS-CoV antibodies.

Findings:

  • The MERS patient exhibited expected antibody responses.
  • No seroconversion was detected in any of the 53 close contacts via IgG antibody enzyme-linked immunosorbent assay (ELISA).

Implications:

  • These findings suggest limited MERS-CoV transmission potential from this imported case.
  • No evidence of community or nosocomial MERS-CoV spread was observed in China.
  • Further surveillance may be warranted to monitor MERS-CoV importation and potential transmission events.